Spotlight Archives - Page 5 of 5 - Pharmaceutical Business review

Pharmaceutical Business review is using cookies

Continue Learn More

Close

Spotlight

- Clinical Trials
- Human Trials
July 26, 2018

Takeda’s Alunbrig improves PFS in phase 3 lung cancer trial

By PBR Staff Writer

The study achieved its primary endpoint at the first pre-specified interim analysis, with Alunbrig showing a statistically significant improvement in PFS compared against crizotinib in adults with anaplastic
Regulation
Approvals
July 23, 2018

Agios Pharmaceuticals secures FDA nod for leukemia treatment Tibsovo

By PBR Staff Writer

Tibsovo, which is an oral and targeted inhibitor of the IDH1 enzyme, is said to be the first and only FDA-approved therapy for patients with R/R AML and
Drug Discovery
Research & Development
June 29, 2018

Biogen to pay $700m to increase stake in Samsung Bioepis

By admin

The US biotechnology company had formed the JV in 2012 with Samsung BioLogics and has held a stake of around 5.4%. Samsung Bioepis is focused on advancing a pipeline